Are there pulmonary sequelae in patients recovering from COVID-19?

被引：0
作者：
Paola Rogliani
Luigino Calzetta
Angelo Coppola
Ermanno Puxeddu
Gianluigi Sergiacomi
Dejanira D’Amato
Antonio Orlacchio
机构：
[1] University of Rome “Tor Vergata”,Unit of Respiratory Medicine, Department of Experimental Medicine
[2] University Hospital “Policlinico Tor Vergata”,Division of Respiratory Medicine
[3] University of Parma,Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit
[4] University of Rome Tor Vergata,Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy
[5] University of Rome “Tor Vergata”,Department of Surgical Sciences, Unit of Radiology
[6] University Hospital “Policlinico Tor Vergata”,Emergency Radiology Unit
来源：
Respiratory Research | / 21卷
关键词：
COVID-19; Pulmonary fibrosis; HRCT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
It has been recently hypothesized that infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to fibrotic sequelae in patients recovering from coronavirus disease 2019 (COVID-19). In this observational study, hospitalized patients with COVID-19 had a HRCT of the chest performed to detect the extension of fibrotic abnormalities via Hounsfield Units (HU). At follow-up, the lung density significantly improved in both lungs and in each lobe of all patients, being in the normal range (− 950 to − 700 HU). This study provides preliminary evidence that hospitalized patients with mild-to-moderate forms of COVID-19 are not at risk of developing pulmonary fibrosis.
引用
收藏
相关论文
共 58 条
  • [1] Spagnolo P(2020)Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 8 750-752
  • [2] Balestro E(2020)Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy Lancet Respir Med 8 807-815
  • [3] Aliberti S(2012)Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report Value Health 15 217-230
  • [4] Cocconcelli E(2020)Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 11 R118-4416
  • [5] Biondini D(2007)Variation in the PaO2/FiO2 ratio with FiO2: mathematical and experimental description, and clinical relevance Crit Care 11 e0152505-109
  • [6] Casa GD(2016)Normal lung quantification in usual interstitial pneumonia pattern: the impact of threshold-based volumetric CT analysis for the staging of idiopathic pulmonary fibrosis PLoS ONE 30 4407-110
  • [7] George PM(2020)CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) Eur Radiol 40 101-undefined
  • [8] Wells AU(2012)Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Eur Respir J 2 105-undefined
  • [9] Jenkins RG(2005)Minimally clinically important difference for the UCSD shortness of breath questionnaire, Borg scale, and visual analog scale COPD 55 2001217-undefined
  • [10] Berger ML(2020)Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Eur Respir J 15 0239235-undefined
123456